抗肿瘤:NGR-hTNF实体瘤化学治疗的疗效绝大部分依赖于化疗药物透过肿瘤组织远端肿瘤细胞的能力.实验证明:由天冬酰胺-甘氨酸-精氨酸(NGR)基序组成的环肽和线性肽可选择性识别肿瘤血管,具有被开发为作用于肿瘤或血管生成组织的抗肿瘤药物的配体导向靶向传递系统的潜力.该类肽与肿瘤新生血管结合的能力取决于其与氨肽酶N(...
Incidence of grade 3–4 adverse events by dose levels. For each dose level of asparagine–glycine–arginine–human tumour necrosis factor (NGR-hTNF) and doxorubicin the following number of cycles were administered, respectively: 0.2–60 : 12–12; 0.2–75 : 27–17; 0.4–75 :...
Methods: Patients (pts) with advanced MPM were treated with low-dose NGR-hTNF given at 0.8 碌g/m2 as 1-hour intravenous infusion every 3 weeks (q3w). This dose was previously selected in phase I trial based on dynamic imaging changes and preliminary clinical activity. The trial had a 2...
NGR-hTNF is a vascular targeting agent that consists of a modified form of human TNF-α fused with an NGR peptide. The NGR peptide moiety of the compound acts by selectively targeting blood vessels, where TNF is released, resulting in the destruction of the tumor's blood supply and subseque...
抗肿瘤药NGR-hTNF介绍 [关键字]:抗肿瘤药NGR-hTNF培美曲塞 健康网讯:
5Universita` Vita-Salute San Raffaele, Via Olgettina, 60, Milan 20132, Italy BACKGROUND: The NGR-hTNF (asparagine–glycine–arginine–human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood...
hTNF抗肿瘤药物医疗产品欧洲委员会授予MolMed公司的用于治疗肝细胞癌(HCC)的抗肿瘤药物NGR—hTNF罕见病药物身份.此项决定基于欧洲医药评价署(EMEA)罕见病医疗产品委员会的肯定意见.NGR—hTNF还因相同适应证被FDA授予罕见病药物身份.代号为NGR008,有40位患者参与的研究该化合物单独给约治疗肝癌的Ⅱ期临床试验的主要...
The tolerability and disease control of NGR-hTNF 0.8 microg/m(2) weekly warrant additional evaluation in patients with advanced MPM.doi:10.1016/S1359-6349(09)71724-0Gregorc, V.Ceresoli, G.L.Zucali, P.A.De Braud, F.G.Bajetta, E....
6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II studyRimassaL.SantoroA.SobreroA.F.SclafaniF.GregorcingentaconnectEuropean Journal of Cancer Supplement...
NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to aminopeptidase N (CD13) overexpressed on tumor blood vessels. In preclinical models, NGR-hTNF has shown potent anti-vascular and antitumor activity, both at low and at high doses. Patients with recurrent or...